News | November 18, 2011

High-Res MRI Can Be Used to Test Cholesterol Drug Efficacy


November 17, 2011 — Westside Medical Imaging of Beverly Hills announces the availability of high resolution magnetic resonance imaging (MRI) with a 3 Tesla magnet to monitor the effects of cholesterol drugs on atherosclerosis.

Norman Lepor, M.D., Hooman Madyoon, M.D., and Michael Duffy, M.D., of Westside Medical Associates of Los Angeles (WMALA) have adopted 3 Tesla MRI using specialized vascular coils to monitor cholesterol drug performance; they do this by following carotid plaque volume and morphology.

According to Lepor, who has reviewed this issue for the upcoming edition of Reviews in Cardiovascular Medicine, "MRI of plaques with a 3 Tesla magnet represents a pivotal development in vascular medicine. It enhances our capability to identify atherosclerotic plaques with a greater degree of sensitivity then carotid intima-media thickness (cIMT) and follow the effects of medical treatments with more accuracy."

Binh Phan, M.D., co-author of this study, found intensive treatment with cholesterol drugs reduced the amount of cholesterol in artery-clogging plaque in 120 patients randomly assigned to receive one of three cholesterol treatments: Lipitor; Lipitor plus Niaspan; or Lipitor plus Niaspan and colesevelam. After three years, the volume of cholesterol decreased from 60.4 cubic mm2 to 37.4 mm2. The percentage of plaque volume consisting of cholesterol decreased from 14.2 percent to 7.4 percent.

According to Madyoon, "because atherosclerosis occurs in blood vessels throughout the body, plaque build-up in carotid arteries is a good surrogate marker for build-up in the coronary arteries indicating a higher risk of heart attack and stroke."

Men over the age of 40 and women approaching menopause with a history of hypertension, elevated cholesterol, diabetes, smoking history or family history of heart disease should consider this exam.

These findings confirmed the theory that cholesterol medications lead to plaque regression by lowering cholesterol levels. According to Lepor, "this MRI technology will also allow physicians to individualize cholesterol therapy rather then treat everyone the same."

According to Duffy, "one of the key advantages of this technology is that you can assess the carotid arteries for plaque progression or regression serially over time since it does not expose the patient to any ionizing radiation."

For more information: www.westsidemedimaging.com


Related Content

News | Pharmaceuticals

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...

Home November 19, 2025
Home
News | Pharmaceuticals

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...

Home September 25, 2025
Home
News | Pharmaceuticals

Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...

Home September 23, 2025
Home
News | Pharmaceuticals

Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular ...

Home September 05, 2025
Home
News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
Subscribe Now